Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success
Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL
The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.
You may also be interested in...
Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.
Entresto and Cosentyx continue to grow but investors will be looking to see if there are candidates in the current portfolio or pipeline that could join them in the mega-blockbuster club.
In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.